
Profitability, historical returns, and peer comparisons.
According to Gilead Sciences, Inc.’s latest financial reports and current stock price. The company's current ROE is -21.74%. This represents a change of 67.54% compared to the average of -12.97% of the last 4 quarters.
The mean historical ROE of Gilead Sciences, Inc. over the last ten years is 26.02%. The current -21.74% ROE has changed -183.56% with respect to the historical average. Over the past ten years (40 quarters), GILD's ROE was at its highest in in the September 2026 quarter at 18.63%. The ROE was at its lowest in in the June 2026 quarter at -88.74%.
Average
26.02%
Median
24.36%
Minimum
0.68%
Maximum
71.48%
Discovering the peaks and valleys of Gilead Sciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 4.27%
Maximum Annual ROE = 71.48%
Minimum Annual Increase = -97.17%
Minimum Annual ROE = 0.68%
| Year | ROE | Change |
|---|---|---|
| 2025 | 37.49% | 1.41% |
| 2024 | 2.48% | -89.99% |
| 2023 | 24.81% | 14.76% |
| 2022 | 21.62% | -26.83% |
| 2021 | 29.55% | 4.27% |
| 2020 | 0.68% | -97.17% |
| 2019 | 23.91% | -6.25% |
| 2018 | 25.51% | 12.66% |
| 2017 | 22.64% | -68.33% |
| 2016 | 71.48% | -26.84% |
The current ROE of Gilead Sciences, Inc. (GILD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
21.59%
5-year avg
23.19%
10-year avg
26.02%
Gilead Sciences, Inc.’s ROE is less than Merck & Co., Inc. (5.29%), less than Pfizer Inc. (4.60%), less than GSK plc (24.64%), less than Johnson & Johnson (19.55%), less than Sanofi (5.52%), less than AstraZeneca PLC (22.31%), less than Novartis AG (24.24%), less than Roche Holding AG (37.12%), less than Eli Lilly and Company (83.65%), greater than AbbVie Inc. (-202.50%),
| Company | ROE | Market cap |
|---|---|---|
| 5.29% | $370.91B | |
| 4.60% | $175.49B | |
| 24.64% | $103.68B | |
| 19.55% | $665.19B | |
| 5.52% | $113.74B | |
| 22.31% | $293.13B | |
| 24.24% | $311.59B | |
| 37.12% | $388.50B | |
| 83.65% | $1.33T | |
| -202.50% | $521.00B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gilead Sciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Gilead Sciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Gilead Sciences, Inc.'s ROE?
How is the ROE calculated for Gilead Sciences, Inc. (GILD)?
What is the highest ROE for Gilead Sciences, Inc. (GILD)?
What is the 3-year average ROE for Gilead Sciences, Inc. (GILD)?
What is the 5-year average ROE for Gilead Sciences, Inc. (GILD)?
How does the current ROE for Gilead Sciences, Inc. (GILD) compare to its historical average?